Manabi-aid Valuation Multiples

Discover revenue and EBITDA valuation multiples for Manabi-aid and similar public comparables like Alfio Bardolla Training, Flier Inc, One-On-One Educational, Dadi Education and more.

Manabi-aid Overview

About Manabi-aid

Manabi-aid Co Ltd is engaged in planning, development and provision of educational services via the Internet / Consulting for educational institutions / Management of cram schools.


Founded

2015

HQ

Japan

Employees

N/A

Financials (FY)

Revenue: $2M
EBITDA: ($1M)

EV

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Manabi-aid Financials

Manabi-aid reported last fiscal year revenue of $2M and negative EBITDA of ($1M).

In the same fiscal year, Manabi-aid generated $999K in gross profit, ($1M) in EBITDA losses, and had net loss of ($1M).


Manabi-aid P&L

In the most recent fiscal year, Manabi-aid reported revenue of $2M and EBITDA of ($1M).

Manabi-aid is unprofitable as of last fiscal year, with gross margin of 43%, EBITDA margin of (46%), and net margin of (49%).

See analyst estimates for Manabi-aid
Last FY202320242025202620272028
Revenue$2M$4M$3M$2M
Gross Profit$999K$3M$1M$865K
Gross Margin43%70%51%40%
EBITDA($1M)$882K($953K)($1M)
EBITDA Margin(46%)24%(37%)(63%)
EBIT Margin(47%)23%(37%)(63%)
Net Profit($1M)$697K($1M)($1M)
Net Margin(49%)19%(43%)(66%)

Financial data powered by Morningstar, Inc.

Manabi-aid Stock Performance

Manabi-aid has current market cap of $7M, and enterprise value of $4M.

Market Cap Evolution


Manabi-aid's stock price is $2.13.

Manabi-aid share price increased by 4.4% in the last 30 days, and decreased by 48.1% in the last year.

Manabi-aid has an EPS (earnings per share) of $-0.33.

See more trading valuation data for Manabi-aid
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M$7M2.4%4.4%3.4%-48.1%$-0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Manabi-aid Valuation Multiples

Manabi-aid trades at 1.9x EV/Revenue multiple, and (4.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Manabi-aid

Manabi-aid Financial Valuation Multiples

As of August 11, 2026, Manabi-aid has market cap of $7M and EV of $4M.

Manabi-aid has a P/E ratio of (6.4x).

Last FY202320242025202620272028
EV/Revenue1.9x1.2x1.7x2.1x
EV/EBITDA(4.1x)5.1x(4.7x)(3.3x)
EV/EBIT(4.1x)5.2x(4.7x)(3.3x)
EV/Gross Profit4.5x1.7x3.4x5.2x
P/E(6.4x)10.4x(6.6x)(5.1x)
EV/FCF(5.9x)15.3x(5.2x)(4.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Manabi-aid Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Manabi-aid Margins & Growth Rates

In the most recent fiscal year, Manabi-aid reported gross margin of 43%, EBITDA margin of (46%), and net margin of (49%).

See estimated margins and future growth rates for Manabi-aid

Manabi-aid Margins

Last FY202420252026202720282029
Gross Margin43%51%40%43%
EBITDA Margin(46%)(37%)(63%)(46%)
EBIT Margin(47%)(37%)(63%)(47%)
Net Margin(49%)(43%)(66%)(49%)
FCF Margin(33%)(33%)(46%)(33%)

Manabi-aid Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth(31%)(15%)7%
Gross Profit Growth(50%)(33%)16%
EBITDA Growth(208%)42%(20%)
EBIT Growth(211%)43%(20%)
Net Profit Growth(257%)31%(21%)
FCF Growth(392%)17%(24%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Manabi-aid Operational KPIs

Manabi-aid's Rule of 40 is (39%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Manabi-aid's Rule of X is (28%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Manabi-aid
Last FY202320242025202620272028
Rule of 40(39%)---
Bessemer Rule of X(28%)---
Opex to Revenue90%47%88%103%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Manabi-aid Competitors

Manabi-aid competitors include Alfio Bardolla Training, Flier Inc, One-On-One Educational, Dadi Education, OpenLearning, Kvix, Execus, Grupo Qumma, NextEd Group and Tellusgruppen.

Most Manabi-aid public comparables operate across Education & Training, Learning Platforms, EduTech and KidsTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Alfio Bardolla Training0.4x0.4x4.7x4.7x
Flier Inc1.2x1.2x27.4x28.0x
One-On-One Educational----
Dadi Education0.6x-9.5x-
OpenLearning4.9x-(4.5x)-
Kvix2.8x-26.2x-
Execus1.1x1.1x9.4x9.4x
Grupo Qumma----

This data is available for Pro users. Sign up to see all Manabi-aid competitors and their valuation data.

Start Free Trial

Manabi-aid VC Funding History

Before going public, Manabi-aid raised $2M in total equity funding, across 3 rounds.


Manabi-aid Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Apr-20SeedObunsha Ventures; K&P Partners$800K--
Oct-18AngelShuuichi Hiromasa$400K--
Aug-18SeedK&P Partners$700K--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Manabi-aid

Who are competitors of Manabi-aid?Manabi-aid main competitors include Alfio Bardolla Training, Flier Inc, One-On-One Educational, Dadi Education, OpenLearning, Kvix, Execus, Grupo Qumma, NextEd Group, Tellusgruppen.

See public comps similar to Manabi-aid

Lists including Manabi-aid

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial